Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. / Lodding, I P; da Cunha Bang, C; Sørensen, S S; Gustafsson, F; Iversen, M; Kirkby, N; Perch, M; Rasmussen, A; Sengeløv, H; Mocroft, A; Lundgren, J D.

In: Open Forum Infectious Diseases, Vol. 5, No. 5, 2018, p. ofy080.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lodding, IP, da Cunha Bang, C, Sørensen, SS, Gustafsson, F, Iversen, M, Kirkby, N, Perch, M, Rasmussen, A, Sengeløv, H, Mocroft, A & Lundgren, JD 2018, 'Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation', Open Forum Infectious Diseases, vol. 5, no. 5, pp. ofy080. https://doi.org/10.1093/ofid/ofy080

APA

Lodding, I. P., da Cunha Bang, C., Sørensen, S. S., Gustafsson, F., Iversen, M., Kirkby, N., ... Lundgren, J. D. (2018). Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 5(5), ofy080. https://doi.org/10.1093/ofid/ofy080

Vancouver

Lodding IP, da Cunha Bang C, Sørensen SS, Gustafsson F, Iversen M, Kirkby N et al. Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases. 2018;5(5):ofy080. https://doi.org/10.1093/ofid/ofy080

Author

Lodding, I P ; da Cunha Bang, C ; Sørensen, S S ; Gustafsson, F ; Iversen, M ; Kirkby, N ; Perch, M ; Rasmussen, A ; Sengeløv, H ; Mocroft, A ; Lundgren, J D. / Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. In: Open Forum Infectious Diseases. 2018 ; Vol. 5, No. 5. pp. ofy080.

Bibtex

@article{dec8495cb66a4513b29a29eaf3ed1234,
title = "Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation",
abstract = "Background: Transplant recipients presenting with cytomegalovirus (CMV) disease at the time of diagnosis of CMV DNAemia pose a challenge to a preemptive CMV management strategy. However, the rate and risk factors of such failure remain uncertain.Methods: Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients with a first episode of CMV polymerase chain reaction (PCR) DNAemia within the first year posttransplantation were evaluated (n = 335). Patient records were reviewed for presence of CMV disease at the time of CMV DNAemia diagnosis. The distribution and prevalence of CMV disease were estimated, and the odds ratio (OR) of CMV disease was modeled using logistic regression.Results: The prevalence of CMV disease increased for both SOT and HSCT with increasing diagnostic CMV PCR load and with screening intervals >14 days. The only independent risk factor in multivariate analysis was increasing CMV DNAemia load of the diagnostic CMV PCR (OR = 6.16; 95{\%} confidence interval, 2.09-18.11). Among recipients receiving weekly screening (n = 147), 16 (10.8{\%}) had CMV disease at the time of diagnosis of CMV DNAemia (median DNAemia load 628 IU/mL; interquartile range, 432-1274); 93.8{\%} of these cases were HSCT and lung transplant recipients.Conclusions: Despite application of weekly screening intervals, HSCT and lung transplant recipients in particular presented with CMV disease at the time of diagnosis of CMV DNAemia. Additional research to improve the management of patients at risk of presenting with CMV disease at low levels of CMV DNAemia and despite weekly screening is warranted.",
author = "Lodding, {I P} and {da Cunha Bang}, C and S{\o}rensen, {S S} and F Gustafsson and M Iversen and N Kirkby and M Perch and A Rasmussen and H Sengel{\o}v and A Mocroft and Lundgren, {J D}",
year = "2018",
doi = "10.1093/ofid/ofy080",
language = "English",
volume = "5",
pages = "ofy080",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation

AU - Lodding, I P

AU - da Cunha Bang, C

AU - Sørensen, S S

AU - Gustafsson, F

AU - Iversen, M

AU - Kirkby, N

AU - Perch, M

AU - Rasmussen, A

AU - Sengeløv, H

AU - Mocroft, A

AU - Lundgren, J D

PY - 2018

Y1 - 2018

N2 - Background: Transplant recipients presenting with cytomegalovirus (CMV) disease at the time of diagnosis of CMV DNAemia pose a challenge to a preemptive CMV management strategy. However, the rate and risk factors of such failure remain uncertain.Methods: Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients with a first episode of CMV polymerase chain reaction (PCR) DNAemia within the first year posttransplantation were evaluated (n = 335). Patient records were reviewed for presence of CMV disease at the time of CMV DNAemia diagnosis. The distribution and prevalence of CMV disease were estimated, and the odds ratio (OR) of CMV disease was modeled using logistic regression.Results: The prevalence of CMV disease increased for both SOT and HSCT with increasing diagnostic CMV PCR load and with screening intervals >14 days. The only independent risk factor in multivariate analysis was increasing CMV DNAemia load of the diagnostic CMV PCR (OR = 6.16; 95% confidence interval, 2.09-18.11). Among recipients receiving weekly screening (n = 147), 16 (10.8%) had CMV disease at the time of diagnosis of CMV DNAemia (median DNAemia load 628 IU/mL; interquartile range, 432-1274); 93.8% of these cases were HSCT and lung transplant recipients.Conclusions: Despite application of weekly screening intervals, HSCT and lung transplant recipients in particular presented with CMV disease at the time of diagnosis of CMV DNAemia. Additional research to improve the management of patients at risk of presenting with CMV disease at low levels of CMV DNAemia and despite weekly screening is warranted.

AB - Background: Transplant recipients presenting with cytomegalovirus (CMV) disease at the time of diagnosis of CMV DNAemia pose a challenge to a preemptive CMV management strategy. However, the rate and risk factors of such failure remain uncertain.Methods: Solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) recipients with a first episode of CMV polymerase chain reaction (PCR) DNAemia within the first year posttransplantation were evaluated (n = 335). Patient records were reviewed for presence of CMV disease at the time of CMV DNAemia diagnosis. The distribution and prevalence of CMV disease were estimated, and the odds ratio (OR) of CMV disease was modeled using logistic regression.Results: The prevalence of CMV disease increased for both SOT and HSCT with increasing diagnostic CMV PCR load and with screening intervals >14 days. The only independent risk factor in multivariate analysis was increasing CMV DNAemia load of the diagnostic CMV PCR (OR = 6.16; 95% confidence interval, 2.09-18.11). Among recipients receiving weekly screening (n = 147), 16 (10.8%) had CMV disease at the time of diagnosis of CMV DNAemia (median DNAemia load 628 IU/mL; interquartile range, 432-1274); 93.8% of these cases were HSCT and lung transplant recipients.Conclusions: Despite application of weekly screening intervals, HSCT and lung transplant recipients in particular presented with CMV disease at the time of diagnosis of CMV DNAemia. Additional research to improve the management of patients at risk of presenting with CMV disease at low levels of CMV DNAemia and despite weekly screening is warranted.

U2 - 10.1093/ofid/ofy080

DO - 10.1093/ofid/ofy080

M3 - Journal article

VL - 5

SP - ofy080

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 5

ER -

ID: 212955092